$15.20
7.34% yesterday
Nasdaq, Sep 04, 10:11 pm CET
ISIN
US4834971032
Symbol
KALV

KalVista Pharmaceuticals, Inc. Stock price

$15.20
+1.89 14.20% 1M
+3.93 34.87% 6M
+6.73 79.46% YTD
+2.28 17.65% 1Y
-0.94 5.82% 3Y
+2.15 16.48% 5Y
-59.56 79.67% 10Y
-62.64 80.47% 20Y
Nasdaq, Closing price Thu, Sep 04 2025
+1.04 7.34%
ISIN
US4834971032
Symbol
KALV
Industry

Key metrics

Basic
Market capitalization
$759.3m
Enterprise Value
$644.6m
Net debt
positive
Cash
$220.6m
Shares outstanding
49.8m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | 21.5
EV/Sales
- | 18.3
EV/FCF
negative
P/B
8.0
Financial Health
Equity Ratio
38.0%
Return on Equity
-
ROCE
-
ROIC
-
Debt/Equity
1.1
Financials (TTM | estimate)
Revenue
- | $35.3m
EBITDA
- | $-168.2m
EBIT
- | $-182.4m
Net Income
- | $-170.8m
Free Cash Flow
$-153.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | -
Net Income
- | -
Free Cash Flow
-71.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -476.5%
EBIT
-
Net
- | -483.9%
Free Cash Flow
-
More
EPS
-
FCF per Share
$-3.1
Short interest
22.5%
Employees
150
Rev per Employee
-
Show more

Is KalVista Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

KalVista Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a KalVista Pharmaceuticals, Inc. forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a KalVista Pharmaceuticals, Inc. forecast:

Buy
94%
Hold
6%

Financial data from KalVista Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Oct '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 81 81
130% 130%
-
- Research and Development Expense 91 91
10% 10%
-
-171 -171
46% 46%
-
- Depreciation and Amortization 0.88 0.88
13% 13%
-
EBIT (Operating Income) EBIT -172 -172
46% 46%
-
Net Profit -156 -156
55% 55%
-

In millions USD.

Don't miss a Thing! We will send you all news about KalVista Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

KalVista Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
about 21 hours ago
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the company will host a live webcast at 8:30 a.m. ET on Thursday, September 11, 2025 to provide an operational update and release financial results for the fiscal quarter ended July 31, 2025. The webcast can be accessed on the Investors section of the Company's website at ...
Neutral
Business Wire
about 21 hours ago
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted two newly-hired employees inducement options to purchase an aggregate of 5,000 shares of KalVista common stock on September 1, 2025 as inducements material to each employee entering into employment with Ka...
Neutral
Business Wire
9 days ago
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 10:55 a.m. ET. A live webcast of the presentation will be available on the Company's website at www.kalvista.com. An audio archive will be av...
More KalVista Pharmaceuticals, Inc. News

Company Profile

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.

Head office United States
CEO Ben Palleiko
Employees 150
Founded 2004
Website www.kalvista.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today